Articles tagged with Cancer Patients
Researchers developed a new technique to analyze frozen tumor specimens, enabling the study of rare cancers and unique patient histories. This breakthrough increases the number and variety of tumor samples available for scientific analysis.
A new study standardizes the use of optical genome mapping (OGM) for patients with blood cancers, demonstrating its potential as a frontline test for diagnosing hematologic malignancies. OGM outperforms existing tests in detecting cancer-causing gene variants and identifying additional information that can improve patient outcomes.
Researchers found that a pro-oxidant mixture of resveratrol and copper can inactivate cell-free chromatin particles, reducing chemotherapy toxicity. The treatment also showed promise in preventing aging and sepsis.
A computational model predicts brain tumour growth using MRI data, providing valuable insights for clinicians. The study uses anonymous patient data to develop a predictive model for glioblastoma multiforme (GBM) growth, which can be used to inform treatment decisions.
A study of 4,768 patients with cancer found that SARS-CoV-2 infection led to delayed or discontinued cancer treatment, exacerbating existing survival inequities. Racial and area-level social determinants were associated with these delays.
A new study found that COVID-19 primarily affected patients with a moderate to critical course, often with comorbidities, whereas many had mild courses despite metastatic melanoma and systemic therapy, recommending continued treatment whenever possible.
Researchers discovered that pre-surgery immunotherapy significantly improved patient outcomes for locally advanced colorectal cancer. The treatment showed substantial longer survival benefits, including low recurrence rates, in patients with mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) CRC.
A novel imaging agent, 68Ga-FAPI, has been shown to reduce the number of false-positive PET/CT findings among cancer patients recently vaccinated for COVID-19. This can help prevent costly follow-up and false management decisions for cancer patients.
Researchers are working to understand the events contributing to pancreatic cancer development by studying gene abnormalities and their effects on the disease. Dr. Krushna Patra's lab is focused on understanding how genetic mutations like GNAS contribute to pancreatic cancer growth.
Scientists have found a way to break down the resistance of mice with neuroendocrine pancreatic cancer to checkpoint blockade immunotherapy. A new drug combination, PD1-IL2v and anti-PD-L1, enhances anti-tumor immunity by stimulating specific T cells and reprogramming macrophages, leading to increased survival rates in tumor-bearing mice.
A new genetic test has been developed to identify ovarian cancer patients who benefit from PARP inhibitors, a treatment option with significant improvements in prognosis. The test has been optimized for the Finnish population and is clinically approved, allowing for targeted treatment and reduced adverse effects.
Researchers from prominent institutions discuss hepatocellular carcinoma's pathogenesis, genomic heterogeneity, and targeted therapy options. The review aims to characterize HCC's complexities and develop clinically relevant biomarkers for better management.
The EMBRACE-I study demonstrated the superiority of personalized brachytherapy in treating locally advanced cervical cancer. A targeted approach using magnetic resonance imaging-defined tumor volume resulted in a high tumor control rate and low risk of recurrence.
A new brief tele-cognitive behavioral therapy, BRIGHT, shows promise in reducing body-image distress among head and neck cancer survivors. The trial found that levels of body-image distress fell significantly for those who received the therapy compared to standard survivorship education.
Spouses of cancer patients experience increased risk of psychiatric disorders requiring specialist care. The study emphasizes the importance of mental health screening and support for these individuals.
Researchers tracked 392 patients with diffuse low-grade glioma over 20 years and found that aggressive surgical removal offered a distinct survival advantage. Smaller tumor sizes were associated with longer survival times, highlighting the importance of early intervention.
Researchers have made a breakthrough in precision oncology for patients with metastatic urothelial carcinoma, identifying that certain cell surface molecules decrease or are absent in these patients, making them resistant to the new drug enfortumab vedotin.
Patients with cancer are at a higher risk of SARS-CoV-2 infection and worse outcomes than those without cancer. Triple vaccination is associated with a lower risk of poor outcomes in these patients.
A study of 187 cancer patients found that delaying antibiotic treatment past 60 minutes didn't affect their 6-month survival rate. However, factors such as symptom severity and time to hospital admission were associated with increased risk of death.
Researchers developed predictive models using serum microRNAs to identify patients at risk of requiring early palliative care. The study used serum samples from 178 patients with various types of cancer and found that miRNA-based models had higher accuracy than clinical models in predicting referral to a palliative care unit.
A cost-effectiveness analysis of direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH) for cancer-associated thrombosis found that DOACs are more medically effective and cost-effective. The most cost-effective DOAC, apixaban, was also shown to be the least costly anticoagulant.
Researchers developed a cell-based method to predict breast cancer treatment responses, showing promising results and potential for personalized medicine. The method uses tumour cells and supporting cells from patients, allowing for efficient drug profiling and accurate treatment prediction.
Research from Michigan Medicine reveals that high levels of ammonia in colon tumors can lead to reduced T cell growth and immunotherapy resistance. A study published in Cell Metabolism found that using an FDA-approved drug to lower ammonia levels made tumors more sensitive to treatment.
Researchers found that plasma GH levels are a potential biomarker for predicting treatment outcomes in patients with advanced HCC treated with Atezo/Bev. The study showed significantly superior overall survival and non-significant trend in favor of GH-low patients compared to GH-high patients.
A systematic review and network meta-analysis found that acupressure has a greater effect on reducing sleep disturbance in patients with cancer. The study suggests that nurses should be trained in acupressure to help patients experiencing sleep problems. The analysis included 24 randomized controlled trials involving 2,002 patients.
Researchers at Michigan Medicine have developed a new biomarker-based strategy to screen for immune checkpoint inhibitor-induced myocarditis, which can cause muscle damage and liver injury. Early detection of these biomarkers can lead to earlier treatment and improved survival rates.
The use of 3D-patient tumor avatars (3D-PTAs) is crucial for guiding treatment decisions in precision oncology. These avatars, including patient-derived organoids, 3D bioprinting, and microscale models, can accurately depict a tumor with its microenvironment, enabling the testing and prediction of therapeutic drug efficacy.
Researchers at IU School of Medicine discovered a genetic variant that may increase the risk of heart damage from anthracycline-based chemotherapy. The study found that this variant can be predicted using human iPSC-derived cardiomyocytes, and potential strategies to prevent cardiotoxicity are being explored.
Researchers at Memorial Sloan Kettering Cancer Center discovered that common cancer treatments cause long-term damage to heart tissue by activating a key inflammatory signaling pathway. Inhibiting this pathway may reduce the risk of cancer survivors developing heart disease later in life.
A large study found that Medicaid expansion under the Affordable Care Act leads to better survival outcomes for young adults aged 18-39 newly diagnosed with cancer. The research showed a significant increase in two-year survival among young adults of Hispanic ethnicity or non-Hispanic Black race.
The study estimated that the NCI-funded NCTN trials have added at least 14.2 million life-years to cancer patients in the US, representing a cost of $326 per year. The trials have had a significant impact on clinical care, with 87.7% of their findings cited as evidence in guidelines and package inserts.
A new multidrug treatment combining pembrolizumab and all-trans retinoic acid has proven effective in treating stage IV melanoma, with an overall response rate of 71% and a one-year overall survival rate of 80%. The study's results are promising for patients who have failed traditional immunotherapy.
Langerhans' Cell Histiocytosis (LCH) is a serious disease affecting children that can be fatal in severe cases. Researchers have identified the origin of LCH cells, which are derived from both dendritic and monocyte cells.
Researchers found that using tixagevimab-cilgavimab in blood cancer patients prevented moderate and severe COVID cases. The antibody provided protection but did not entirely prevent infection, highlighting the importance of additional safety measures.
A team led by Abhinav Jha is developing a novel low-count quantitative single photon emission computed tomography (LC-QSPECT) method to measure the concentration of radiopharmaceutical material in tumors and vital organs. This technique aims to provide accurate measurements of absorbed dose from radiation therapy, helping plan treatmen...
Researchers identify CDK4 and filamin proteins as predictors of response to paclitaxel in HER2-negative breast cancer patients. High levels of these proteins are associated with a positive response rate in 90% of cases.
A comprehensive genetic testing protocol increased patient compliance with recommended testing from 33.3% to 98.7%, while also reducing turnaround time for genetic test results.
Researchers describe results using cladribine-based combination epigenetic and immunotherapy in MCL, achieving an increased overall survival greater than 40 months with durable remissions without relapse for longer than 5 years. The approach is promising in the treatment of MCL and potentially other previously treatment-refractory canc...
A new study from Edith Cowan University found that a single bout of exercise can significantly suppress tumour growth in people with late-stage prostate cancer. The researchers observed increased levels of anti-cancer myokines after high-intensity exercise, which helped fight cancerous cells and stimulated anti-cancer processes.
The E1910 trial found that adding blinatumomab to standard front-line consolidation chemotherapy improved overall survival and kept most patients in remission. The treatment, which targets malignant B cells, demonstrated its effectiveness in patients with a good prognosis after an initial round of chemotherapy.
A recent study by City of Hope found that only 30% of patients with advanced neuroendocrine tumors prioritize living longer as their top goal. Instead, 70% focus on addressing pain, fatigue, and losing function. The research highlights the need for better communication between care providers and patients to develop personalized treatme...
A new clinical trial has found that chemotherapy before surgery significantly improves 1-year survival rates for patients with borderline resectable pancreatic cancer. The study, led by the University of Liverpool, compared immediate surgery with short-course neoadjuvant therapy and found a significant survival benefit.
A new study by City of Hope found that neuroendocrine cancer patients value overcoming pain, fatigue, or lack of function over prolonging life. Only half of the time do patients and doctors agree on treatment goals.
A unique clinical trial has achieved a remarkable 97% induction survival rate in patients with acute promyelocytic leukemia (APL) by providing a simplified treatment regimen and 24/7 support from APL experts. This collaborative care model, known as EA9131, significantly reduced early deaths and improved overall survival rates.
A nationwide retrospective study showed that adjuvant chemotherapy after neo-adjuvant chemotherapy and surgery significantly improved overall survival in patients with pancreatic adenocarcinoma, regardless of lymph node status or resection margins. The study included nearly 900 patients and was published in JAMA Oncology.
Researchers found that activating the non-mutated form of P53 can change the fundamental makeup of cancer stem cells in mouse models of mucoepidermoid carcinoma. This new therapy approach shows promise for treating this lethal form of salivary gland cancer.
The SERENA-2 trial found camizestrant significantly improves progression-free survival versus fulvestrant in patients with estrogen receptor-positive, HER2-negative breast cancer. Camizestrant demonstrates efficacy across various patient populations, including those with ESR1 mutations and prior CDK4/6 inhibitor treatment.
The TIL trial has demonstrated that cell therapy using patient's own immune cells is an extremely powerful immunotherapy for metastatic melanoma, with significant shrinkage of metastases in half of patients. Progression-free survival after six months was 53%, significantly better than standard immunotherapy with ipilimumab.
The updated guideline provides recommendations on the use of radiation therapy and systemic therapy after surgery to treat patients with endometrial cancer. It considers the role of surgical staging and molecular profiling techniques in determining whether a patient should receive post-operative therapy.
A study published in the Journal of Medical Imaging and Radiation Sciences found that hospital parking fees significantly correlate with cancer center address transit score and city cost of living across Western Canada. Cities with higher cost of living have less free parking, exacerbating economic burdens on patients.
Researchers at UNIGE and LMU discovered that immune system's anti-tumour activity peaks in the morning. Tumours implanted at night grew faster than those implanted in the afternoon. Administering immunotherapy treatments early morning significantly enhanced their effectiveness, suggesting a new strategy for cancer treatment.
Scientists conducted whole-body PET scans using a radioactively labeled antibody tracer against CD8+ T-cells before and after starting immune checkpoint inhibitors. The results showed heterogeneous and dynamic responses among patients, revealing the complexity of the immunotherapy response.
A study found that medical marijuana legalization was associated with reduced opioid use and fewer pain-related hospitalizations among adults receiving cancer treatment. The results suggest potential benefits for patient safety and quality of life, but further investigation is needed to understand the nature of these associations.
For adrenal lesions evaluated by single-phase dual-energy CT, fat fraction had significantly higher sensitivity than virtual noncontrast attenuation at both clinically optimal threshold and traditional ≤10 HU threshold. Fat fraction-derived metrics can help definitively diagnose incidental adrenal lesions as adenomas.
Research on Fanconi anemia reveals its link to aggressive head-and-neck tumors due to gene-copy chaos, increasing the need for new treatments. The study also highlights a connection between smoking and drinking and elevated cancer risk.
A study found that cryoablation, a freezing-based treatment, reduces cancer-specific mortality in patients with early-stage renal cell carcinomas (RCCs) measuring between 3 and 4 centimeters. In contrast, heat-based thermal ablation has been shown to have a higher risk of death from kidney cancer for these patients.
Researchers review myeloid-derived suppressor cells' phenotypes, mechanisms of immunosuppression, and roles in cancer treatment. Studies on non-malignant diseases, such as autoimmune disorders and obesity, are lacking, highlighting the need for further investigation.
Researchers at the University of Waterloo have identified a new method for scheduling radiation therapy that could be up to 22% more effective at killing cancer cells. The algorithm takes into account the differing radiation resistances of stem cells and non-stem cells, allowing doctors to predict how a tumour will respond to treatment.
Researchers at CU Anschutz Medical Campus have identified a less invasive way to treat HPV-unrelated head and neck squamous cell carcinomas by combining radiation with immunotherapy. The approach resulted in remarkable success rates, including 75% of patients experiencing major pathological responses or complete responses.
Researchers analyzed genetic data from 233 patients with ovarian cancer and found that precise localization of BRCA gene mutations is crucial for effective treatment. The study suggests that PARP inhibitors can be highly effective in patients with mutations in the DNA-binding domain, leading to improved overall survival rates.